Sugi Predict

Sugi Predict / Compounds / SCHEMBL435275

SCHEMBL435275

SCHEMBL435275

Fc1ccc(-c2cc[c]cc2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ DHFR P00374 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ ALB P02768 1/20 0.46
▸ HMGB1 P09429 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CXCL12 P48061 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ SLC22A6 Q4U2R8 1/20 0.46
▸ ACMSD Q8TDX5 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ GRM2 Q14416 2/20 0.39
▸ HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533219 0.83 CA9 (0.38) TTRALDH1A1KDM4EMEN1USP2
SCHEMBL9057929 0.81 ALDH1A1 (0.52) TTRALDH1A1KDM4EMEN1USP2
SCHEMBL6671944 0.81 CA9 (0.46) TTRALDH1A1KDM4EMEN1USP2
SCHEMBL5321818 0.79 PDE3B (0.36) MEN1LMNAHPGDKMT2AHIF1A
SCHEMBL434681 0.79 GRM2 (0.41) GRM2APPCNR1KMO
SCHEMBL3543657 0.79 NISCH (0.45) KDM4EGRM2
SCHEMBL4009381 0.79 ALOX5AP (0.43) TTRALDH1A1KDM4EMEN1USP2
SCHEMBL5917584 0.79 NMT1 (0.38) GRM2
SCHEMBL11488969 0.79 PIK3R1 (0.32) TTRALDH1A1KDM4EMEN1USP2
SCHEMBL436196 0.78 TTR (0.46) TTRALDH1A1KDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10076517-B2 Methods and pharmaceutical compositions for the treatment of fibrosis INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) 2018-09-18 — — US claimed
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 — — EP claimed
EP-2421825-B9 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-20 — — EP claimed
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE INDUSTRIES, LTD. (JP) 2014-04-24 — — US claimed
US-8691805-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-04-08 — — US claimed
EP-2421825-B1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-01-01 — — EP claimed
US-20130244997-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-09-19 — — US claimed
US-8455476-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-06-04 — — US claimed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 — — US claimed
EP-2421825-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 — — EP claimed
CN-101193635-A Multicyclic compounds and methods of their use LEXICON GENETICS INC (US) 2008-06-04 — — CN claimed
US-6962942-B2 Azacycloalkanone serine protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-11-08 — — US claimed
EP-1212300-B1 AZACYCLOALKANONE SERINE PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 2003-11-05 — — EP claimed
US-20030109517-A1 Azacycloalkanone serine protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-06-12 — — US claimed
US-6469029-B1 INHIBITORS OF THROMBIN PRODUCTION VIA FACTOR XA INHIBITION; COUPLED TO MEDICAL DEVICES, SUCH AS STENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-10-22 — — US claimed
EP-1212300-A1 AZACYCLOALKANONE SERINE PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2002-06-12 — — EP claimed
WO-2001019795-A1 AZACYCLOALKANONE SERINE PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-03-22 — — WO claimed
US-4973691-A ANALGESICS Spojene Podniky Prozdravotnickou Vyrobu (SPOFA) (CS) 1990-11-27 — — US claimed
US-4151302-A Araliphatic dihalogen compounds composition and method of use MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1979-04-24 — — US claimed
US-4057647-A Araliphatic dihalogen compounds and process for their preparation MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-11-08 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10076517-B2 Methods and pharmaceutical compositions for the treatment of fibrosis LIPA, MGLL, PNLIP TTR 1630/4885ALDH1A1 779/4885KDM4E 1727/4885
US-20130244997-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA TTR 3120/4885ALDH1A1 364/4885KDM4E 1931/4885
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 TTR 4377/4885ALDH1A1 204/4885KDM4E 2779/4885
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 TTR 1028/4885ALDH1A1 377/4885KDM4E 3706/4885
US-20030109517-A1 Azacycloalkanone serine protease inhibitors CTRL, SERPINE1, SERPINB1 TTR 2257/4885ALDH1A1 3935/4885KDM4E 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.